Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 117.25% | 60.94% | -17.45% | 67.32% | 24.33% |
| Gross Profit | -117.25% | -60.94% | 17.45% | -67.32% | -24.33% |
| SG&A Expenses | 30.95% | 41.09% | 30.63% | 50.19% | 45.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.06% | 55.01% | 34.70% | 61.24% | 30.12% |
| Operating Income | -91.06% | -55.01% | -34.70% | -61.24% | -30.12% |
| Income Before Tax | -109.36% | -60.17% | -62.59% | 12.41% | -26.04% |
| Income Tax Expenses | 37.50% | -47.62% | -- | -- | -- |
| Earnings from Continuing Operations | -108.95% | -59.06% | -63.89% | 12.12% | -26.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.95% | -59.06% | -63.89% | 12.12% | -26.76% |
| EBIT | -91.06% | -55.01% | -34.70% | -61.24% | -30.12% |
| EBITDA | -91.05% | -55.02% | -34.92% | -61.25% | -30.18% |
| EPS Basic | -43.13% | -19.24% | -6.40% | 40.65% | 16.51% |
| Normalized Basic EPS | -43.45% | -20.04% | -5.55% | -5.35% | 17.00% |
| EPS Diluted | -43.13% | -19.24% | -6.40% | 40.65% | 16.51% |
| Normalized Diluted EPS | -43.45% | -20.04% | -5.55% | -5.35% | 17.00% |
| Average Basic Shares Outstanding | 45.99% | 33.41% | 54.02% | 48.05% | 51.80% |
| Average Diluted Shares Outstanding | 45.99% | 33.41% | 54.02% | 48.05% | 51.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |